TRIB TRINITY BIOTECH PLC

Nasdaq trinitybiotech.com


$ 1.00 $ 0.00 (0 %)    

Friday, 31-Oct-2025 15:59:40 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 1
$ 1.00
$ 0.90 x 500
$ 1.04 x 50
$ 0.94 - $ 1.02
$ 0.88 - $ 17.20
39,719
na
17.96M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trinity-biotech-regains-nasdaq-compliance

Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and dia...

 trinity-biotech-announces-clinical-trial-results-demonstrating-technical-breakthrough-and-de-risking-commercial-pathway-for-its-next-gen-continuous-glucose-monitoring-technology-called-cgm

Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes managemen...

 mhra-says-received-reports-describing-positive-bias-in-hba1c-results-delivered-by-trinity-biotech-premier-hb9210-hba1c-analyser-says-positive-bias-in-hba1c-results-resulted-in-patients-being-incorrectly-diagnosed-as-pre-diabetic-or-diabetic-trinity-biotech-committed-to-updating-intended-use-statement-in-the-instructions-for-use

https://www.gov.uk/drug-device-alerts/trinity-biotech-premier-hb9210-hba1c-analyser-risk-of-positive-bias-and-updates-to-instru...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION